Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Protalix BioTherapeutics CEO David Aviezer To Retire - Quick Facts

RELATED NEWS
Trade PLX now with 

Protalix BioTherapeutics Inc. (PLX: Quote) announced that David Aviezer has decided to retire after almost 12 years from his role as the Company's President and Chief Executive Officer. He will retire this year upon the completion of a process to nominate his successor.

In the meantime, Aviezer will continue serving as President and Chief Executive Officer and remains a member of the Board of Directors.

The company's Board will appoint a committee to select a new Chief Executive Officer.

Click here to receive FREE breaking news email alerts for Protalix BioTherapeutics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
With trading resuming following the long, holiday weekend, stocks showed a lack of direction throughout the trading session on Tuesday before ending the day mixed. The markets largely held on to the bulk of their recent gains. The Islamic State (IS), a Sunni extremist group previously known as Islamic State of Iraq and the Levant (ISIL), has released a video purporting to show the beheading of US journalist Steven Sotloff, media reports said Tuesday. According to reports, the video also showed a masked man threatening to execute a British man named David Haines. He also warned governments to stay away "this evil allian Less than a month after resigning from Congress, former House Majority Leader Eric Cantor, R-Virg., has made the move from Washington to Wall Street by joining boutique investment bank Moelis & Co. A statement from Moelis said Cantor will serve as Vice Chairman and Managing Director and also be elected to the company's Board of Directors.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.